During the past three decades, clinical expression of BD in Korea has changed, resulting in fewer instances of complete type disease, declining male propensity, and shifting patterns of organ involvement.
In this study, we assessed the infiltrating inflammatory cells and cytokine expression of acute cutaneous lesions in BD through immunohistochemical staining of BD-related skin lesions. Further studies about the disease activity and the molecular biology underlying the cutaneous inflammation are needed to understand the detailed pathogenesis of BD.
trial studies combination transarterial chemoembolization (TACE) and Stereotactic Body Radiation Therapy (SBRT) for BCLC A patients with HCC from 4-7 cm. Materials/Methods: Patients were eligible if they were BCLC A, Child-Pugh score 7, had a single HCC from 4-7 cm, no evidence of macrovascular invasion, no evidence of metastatic disease, ECOG 0, and were not suitable for resection or liver transplantation. Treatment consisted of drug-eluting bead (DEB)-TACE at time 0 and 1 month followed by SBRT completed within 2-3 weeks following TACE. Each DEB-TACE treatment utilized 1 vial of 100-300 micron LC Beads (BTG) loaded with 50mg of doxorubicin. SBRT was delivered from 35-50 Gy in 5 fractions. The primary end-point of the study was best objective response by mRECIST (measured 1 month post-treatment and every 3 months thereafter). Secondary endpoints were progression free survival (PFS), cancer specific survival (CSS), overall survival (OS) assessed using the Kaplan-Meier method.Results: From 2014-2018, 25 patients were enrolled in a single institution with a median follow of 18 months (range 1-47). Baseline patient characteristics are shown in Table 1. Every patient completed the protocol as planned except one who only received DEB-TACEx1 before SBRT. 24 patients had at least one post treatment scan to assess mRECIST response (one patient lost to follow up). Best objective response in the target lesion was 92%: 64% complete response (nZ16), 28% partial response (nZ7), 0%stable disease, and 4% progression of disease (nZ1). Median time to CR was 3 months (range 1-17). 1-and 2-year OS was 80% and 67%, respectively. 1-and 2-year PFS was 67% and 52%, respectively. CSS was 91% at 1 year and 83% at 2 years. Conclusion: Preliminary results from this Phase II trial show very promising response rates when combining TACE+SBRT in large, unresectable HCC with excellent OS, PFS, and CSS. These preliminary data are currently being confirmed in an expanded cohort.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.